<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">The co-primary efficacy endpoint of collection of ≥5 × 10
 <sup>6</sup> CD34
 <sup>+</sup> cells/kg was achieved by 18 of 30 (60.0%) patients in the FD group and 17 of 31 (54.8%) patients in the WB group (Fig. 
 <xref rid="Fig1" ref-type="fig">1</xref>; Supplementary Table S
 <xref rid="MOESM3" ref-type="media">2</xref>). The difference between dosing groups was not statistically significant (odds ratio, 1.91; 95% CI 0.44, 9.17; 
 <italic>P</italic> = 0.395).
</p>
